Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 55

1.

MMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapy.

Shiozawa K, Yamane T, Murata M, Yoshihara R, Tsumiyama K, Imura S, Shiozawa S.

Arthritis Res Ther. 2016 Feb 27;18(1):55. doi: 10.1186/s13075-016-0948-7.

2.

Making smart investment decisions in clinical research.

Bansback N, Keystone E, O'Dell J, Phibbs CS, Hannagan K, Brophy M, Anis A.

Trials. 2015 Dec 29;16:590. doi: 10.1186/s13063-015-1123-1.

3.

Increasing obesity and comorbidity in patients undergoing primary total hip arthroplasty in the U.S.: a 13-year study of time trends.

Singh JA, Lewallen DG.

BMC Musculoskelet Disord. 2014 Dec 17;15:441. doi: 10.1186/1471-2474-15-441.

4.

Feasibility of tailored treatment based on risk stratification in patients with early rheumatoid arthritis.

Markusse IM, de Vries-Bouwstra JK, Han KH, van der Lubbe PA, Schouffoer AA, Kerstens PJ, Lems WF, Huizinga TW, Allaart CF.

Arthritis Res Ther. 2014 Sep 25;16(5):430. doi: 10.1186/s13075-014-0430-3.

5.

Regular examinations for toxic maculopathy in long-term chloroquine or hydroxychloroquine users.

Nika M, Blachley TS, Edwards P, Lee PP, Stein JD.

JAMA Ophthalmol. 2014 Oct;132(10):1199-208. doi: 10.1001/jamaophthalmol.2014.1720.

6.

Randomised comparison of initial triple DMARD therapy with methotrexate monotherapy in combination with low-dose glucocorticoid bridging therapy; 1-year data of the tREACH trial.

de Jong PH, Hazes JM, Han HK, Huisman M, van Zeben D, van der Lubbe PA, Gerards AH, van Schaeybroeck B, de Sonnaville PB, van Krugten MV, Luime JJ, Weel AE.

Ann Rheum Dis. 2014 Jul;73(7):1331-9. doi: 10.1136/annrheumdis-2013-204788. Epub 2014 May 1.

7.

Selection bias in rheumatic disease research.

Choi HK, Nguyen US, Niu J, Danaei G, Zhang Y.

Nat Rev Rheumatol. 2014 Jul;10(7):403-12. doi: 10.1038/nrrheum.2014.36. Epub 2014 Apr 1. Review.

8.

Efficacy of conventional synthetic disease-modifying antirheumatic drugs, glucocorticoids and tofacitinib: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.

Gaujoux-Viala C, Nam J, Ramiro S, Landewé R, Buch MH, Smolen JS, Gossec L.

Ann Rheum Dis. 2014 Mar;73(3):510-5. doi: 10.1136/annrheumdis-2013-204588. Epub 2014 Jan 6. Review.

9.

Time trends in the characteristics of patients undergoing primary total knee arthroplasty.

Singh JA, Lewallen DG.

Arthritis Care Res (Hoboken). 2014 Jun;66(6):897-906. doi: 10.1002/acr.22233.

10.

Trajectory of intensive treat-to-target disease modifying drug regimen in an observational study of an early rheumatoid arthritis cohort.

White D, Pahau H, Duggan E, Paul S, Thomas R.

BMJ Open. 2013 Jul 31;3(7). pii: e003083. doi: 10.1136/bmjopen-2013-003083.

11.

Cost per responder of TNF-α therapies in Germany.

Gissel C, Repp H.

Clin Rheumatol. 2013 Dec;32(12):1805-9. doi: 10.1007/s10067-013-2332-1. Epub 2013 Jul 23.

12.

Methotrexate in rheumatoid arthritis: a quarter century of development.

Weinblatt ME.

Trans Am Clin Climatol Assoc. 2013;124:16-25. Review.

13.

Validation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trial.

O'Dell JR, Curtis JR, Mikuls TR, Cofield SS, Bridges SL Jr, Ranganath VK, Moreland LW; TEAR Trial Investigators.

Arthritis Rheum. 2013 Aug;65(8):1985-94. doi: 10.1002/art.38012.

14.

Dendritic cells and the promise of antigen-specific therapy in rheumatoid arthritis.

Thomas R.

Arthritis Res Ther. 2013 Feb 4;15(1):204. doi: 10.1186/ar4130. Review.

15.

Old drugs, old problems: where do we stand in prediction of rheumatoid arthritis responsiveness to methotrexate and other synthetic DMARDs?

Romão VC, Canhão H, Fonseca JE.

BMC Med. 2013 Jan 23;11:17. doi: 10.1186/1741-7015-11-17. Review.

16.

Current imaging strategies in rheumatoid arthritis.

Zeman MN, Scott PJ.

Am J Nucl Med Mol Imaging. 2012;2(2):174-220. Epub 2012 Mar 28.

17.
18.

Methotrexate: optimizing the efficacy in rheumatoid arthritis.

Braun J.

Ther Adv Musculoskelet Dis. 2011 Jun;3(3):151-8. doi: 10.1177/1759720X11408635.

19.

A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial.

Moreland LW, O'Dell JR, Paulus HE, Curtis JR, Bathon JM, St Clair EW, Bridges SL Jr, Zhang J, McVie T, Howard G, van der Heijde D, Cofield SS; TEAR Investigators.

Arthritis Rheum. 2012 Sep;64(9):2824-35. doi: 10.1002/art.34498.

20.

Immune Modulation as Adjunctive Therapy for Pneumocystis pneumonia.

Wang J, Wright TW, Gigliotti F.

Interdiscip Perspect Infect Dis. 2011;2011:918038. doi: 10.1155/2011/918038. Epub 2011 Aug 29.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk